-+ 0.00%
-+ 0.00%
-+ 0.00%

Guggenheim Maintains Buy on Spyre Therapeutics, Raises Price Target to $135

Benzinga·11/04/2026 15:23:37
Listen to the news
Guggenheim analyst Yatin Suneja maintains Spyre Therapeutics (NASDAQ:SYRE) with a Buy and raises the price target from $130 to $135.